



An intramolecular one-pot synthesis of steroidal triazoles via 1,3-dipolar cycloadditions of in situ generated diazo compounds

Marija N. Sakač^{a,*}, Andrea R. Gaković^a, János J. Csanádi^a, Evgenija A. Djurendić^a, Olivera Klisurić^b, Vesna Kojić^c, Gordana Bogdanović^c, Katarina M. Penov Gaši^a

^a Department of Chemistry, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21 000 Novi Sad, Serbia

^b Department of Physics, Faculty of Sciences, University of Novi Sad, 21000 Novi Sad, Trg Dositeja Obradovića 4, Serbia

^c Oncology Institute of Vojvodina, Institutski put 4, 21204 Sremska Kamenica, Serbia

ARTICLE INFO

Article history:

Received 15 February 2009

Revised 13 April 2009

Accepted 28 April 2009

Available online 3 May 2009

Keywords:

Steroidal triazoles

1,3-Dipolar cycloaddition

Nitriles

Dipolarophiles

In vitro cytotoxicity

ABSTRACT

A novel synthetic route is reported for the preparation of steroidal triazoles via intramolecular 1,3-dipolar cycloaddition of a steroidal 16,17-seco-17-diazo-16-nitrile system. The structures of the products are established by X-ray and NMR studies. The in vitro antiproliferative activity of the steroidal triazoles against three tumor cell lines was evaluated.

© 2009 Elsevier Ltd. All rights reserved.

The 1,3-dipolar cycloaddition reaction is a powerful synthetic protocol for the synthesis of five-membered heterocycles via well-designed intramolecular sequences.¹ On the other hand, steroidal C-17 tethered heterocyclic compounds possess high antiproliferative activity toward breast and prostate cancer cell lines.² Steroidal[3,2-*c*]triazoles possess anti-androgenic activity.³ Several nonsteroidal cytochrome P450 aromatase inhibitors containing a triazole ring (such as anastrozole and letrozole), exhibit potent antiproliferative activity against estrogen receptor positive breast adenocarcinoma MCF-7 and inhibit the growth of two different MCF-7 breast tumor xenografts in nude mice.^{4,5} This inspired us to synthesize 1,2,3-triazole androgen and estrogen D-ring-fused derivatives via a 1,3-dipolar cycloaddition reaction, and to evaluate their antiproliferative activity. We used the 17-oxo-16,17-seco-16-nitriles **1** and **2**, which were synthesized earlier as substrates.^{6,7} Compounds **1** and **2** were transformed into the corresponding tosylhydrazones **3** and **4** (Scheme 1). The reactions were carried out in refluxing ethanol over 2 h to afford hydrazones **3** and **4** in yields of 86% and 72%, respectively.

Aggarwal et al.⁸ have reported previously that intermolecular 1,3-dipolar cycloaddition of diazo compounds onto alkenes and alkynes led to substituted pyrazoles. In this Letter, we report the synthesis of 1,2,3-triazoles via intramolecular 1,3-dipolar cycloadditions

of diazo groups, generated in situ from hydrazones **3** and **4**, to a nitrile group. Thus, addition of NaOH in dioxane/H₂O, NaBH₄ in ethanol, or LiAlH₄ in dioxane, to tosylhydrazones **3** and **4** yielded the sodium salts **3a** and **4a**, further heating of which at reflux gave the 17-diazo compounds **5** and **6**. These in situ formed diazo compounds underwent intramolecular 1,3-dipolar cycloaddition to give the D-ring-fused triazole derivatives **7** and **8**. The structure of triazole **7**, which was previously prepared as a byproduct⁹ under different reaction conditions, was established on the basis of spectroscopic data,¹⁰ and X-ray analysis¹¹ (Fig. 1), whereas the structure of triazole **8** was established based on detailed spectroscopic data.¹²


Comprehensive analysis of the one- and two-dimensional NMR data of **8** including the results of ¹³C DEPT, ¹H–¹H COSY, HSQC, and HMBC (500 MHz) experiments, allowed us to establish the structure of **8**. The strong HMBC correlations between the CH₃-18 methyl protons and C-17 (signal at 161.34 ppm) confirmed that the cycloaddition reaction took place at the C-17 position. The equally strong HMBC correlations between the NH proton and the C-16 and C-17 quaternary carbons suggested the symmetrical triazole structure of **8** in DMSO solution, while according to X-ray analysis this hydrogen is positioned on N-1.

In the case of compound **8** the benzyl protection was removed by catalytic hydrogenolysis in the presence of 10% Pd/C, which resulted in the steroidal triazole **9**¹³ in a yield of 65%.

The steroidal triazoles **7** and **9** were preliminarily evaluated for their antiproliferative activity against three human tumor cell

* Corresponding author. Tel.: +38 1214852756; fax: +38 121454065.

E-mail address: marijas@ih.ns.ac.yu (M.N. Sakač).



Scheme 1. Reagents and conditions: (i) TsNHNH₂, EtOH, reflux, 2 h, 86% of **3**, 72% of **4**; (ii) NaOH, dioxane/H₂O, reflux, 1 h for **7**, or 2 h for **8**, 55% of **7**, and 61% of **8**, NaBH₄, EtOH, reflux, 3 h, 65% of **7**, 76% of **8**, or LiAlH₄, dioxane, reflux, 6 h, 69% of **7**; (iii) H₂, 10% Pd/C, MeOH, CH₂Cl₂, rt, 45 h, 65%.




Figure 1. ORTEP representation of the X-ray structure of **7**.

lines. Table 1 shows 50% inhibitory concentrations (IC₅₀) of the tested compounds against human breast adenocarcinoma ER⁺, MDA-MB-231, breast adenocarcinoma ER⁺, MCF-7, prostate cancer

Table 1

IC₅₀ (μM)^a values of the steroidal triazole derivatives **7** and **9** and Doxorubicin,^b in vitro, against different cancer cells

Compound	MDA-MB-231	MCF-7	PC-3	MRC-5
7	>100	>100	12.27	>100
9	20.24	>100	108.64	>100
Doxorubicin	0.12	0.75	95.61	0.12

^a Inhibitory concentrations (IC₅₀) were determined through the use of an established SRB method.¹⁴

^b Doxorubicin (adriamycin) served as reference compound.

PC-3, and normal fetal lung fibroblasts, MRC-5 cells. The results show that the triazole derivative **7** exhibited significant antiproliferative activity and selectivity against PC-3 cells, being almost eight times more potent than Doxorubicin. Compound **9** was active against MDA-MB-231, and was inactive against the MCF-7 and PC-3 cell lines. Both compounds were nontoxic against healthy MRC-5 cells, in contrast to Doxorubicin, which was extremely toxic against these cells.

In conclusion, we have developed a very simple and convenient route for the synthesis of a steroidal 16,17-fused 1,2,3-triazole derivatives. This method involves the intramolecular 1,3-dipolar cycloaddition of a diazo group, generated in situ from C-17-hydrazones onto a C-16-nitrile group in 16,17-secosteroids. Triazole **7** showed potent antiproliferative activity against prostate cancer PC-3 cells, and can serve as the basis for obtaining more active agents against these cells. Compounds **7** and **9** did not exhibit any cytotoxicity toward normal fetal lung MRC-5 cells.

Acknowledgments

We thank the Ministry of Science and Technological Development of the Republic of Serbia for financial support (Grant No. 142052). We also thank Dr. Gyula Batta from the University of Debrecen for two-dimensional 500 MHz NMR spectra.

References and notes

- (a) Frank, É.; Wölfling, J.; Aukshi, B.; König, V.; Schneider, T. R.; Schneider, G. *Tetrahedron* **2002**, 58, 6843–6849; (b) Rogue, D. R.; Neill, J. L.; Antoon, J. W.; Stevens, E. P. *Synthesis* **2005**, 2497–2502; (c) Amantini, D.; Fringuelli, F.; Piermatti, O.; Pizzo, F.; Zunino, E.; Vaccaro, L. *J. Org. Chem.* **2005**, 70, 6526–6529.

2. Jourdan, F.; Bubert, C.; Leese, M. P.; Smith, A.; Ferrandis, E.; Regis-Lydi, S.; Newman, S. P.; Purohit, A.; Reed, M. J.; Potter, B. V. L. *Org. Biomol. Chem.* **2008**, *6*, 4108–4119.
3. Hofmeister, H.; Bittler, D.; Michna, H.; Habenicht, U.; Fritzemeier, K.-H.; Nishino, Y. U. S. Patent 5,389,624, 1995; DE 4,021,433, 1990; *Chem. Abstr.* **1991**, *116*, 152152c.
4. Liu, G.; Marrinan, C. H.; Taylor, S. A.; Black, S.; Basso, A. D.; Kirschmeier, P.; Bishop, W. R.; Liu, M.; Long, B. J. *Anti-Cancer Drugs* **2007**, *18*, 923–931.
5. Brodie, A.; Sabnis, G.; Jelovac, D. *Steroid Biochem. Mol. Biol.* **2006**, *102*, 97–102.
6. Miljković, D.; Petrović, J.; Stajić, M.; Miljković, M. *J. Org. Chem.* **1973**, *38*, 3585–3588.
7. Jovanović-Šanta, S.; Andrić, S.; Kovačević, R.; Pejanović, V. *Collect. Czech. Chem. Commun.* **2000**, *65*, 77–82.
8. Aggarwal, V. K.; de Vicente, J.; Bonnert, R. V. *J. Org. Chem.* **2003**, *68*, 5381–5383.
9. Jindal, D. P.; Gupta, R.; Kaushal, R.; Singh, J. B.; Yadav, M. R. *Indian J. Chem.* **1996**, *35B*, 775–778.
10. *Selected data for 7*: mp 299 °C (from MeOH); IR ν_{\max} 3426 and 3241 (OH and NH); ^1H NMR (250 MHz, DMSO- d_6): δ 0.93 (s, 3H, H-18), 1.02 (s, 3H, H-19), 1.97 (m, 1H, H-14), 2.15 (m, 2H, H-4), 2.33 (dd, 1H, $J_{14,15\beta} = 11.2$, $J_{15\alpha,15\beta} = 14.2$ Hz, H-15 β), 2.58 (dd, 1H, $J_{14,15\alpha} = 6.1$, $J_{15\alpha,15\beta} = 14.2$ Hz, H-15 α), 3.27 (m, 1H, H-3), 4.64 (d, 1H, $J = 4.5$ Hz, OH), 5.31 (m, 1H, H-6), 14.00 (br s, 1H, NH); ^{13}C NMR (62.9 MHz, DMSO- d_6): δ 17.94 (CH₃), 19.09 (CH₃), 19.95 (CH₂), 23.27 (CH₂), 30.21 (CH), 30.73 (CH₂), 31.39 (CH₂), 33.68 (CH₂), 36.37 (qC), 36.73 (CH₂), 38.71 (qC), 42.22 (CH₂), 49.96 (CH), 61.49 (CH), 69.96 (CH), 120.00 (C-6), 141.57 (C-5), 152.20 (C-16), 161.42 (C-17); HR MS: m/z 312.2079 ($\text{M}^+ - \text{H}$); calcd for C₁₉H₂₆N₃O: 312.2081.
11. X-ray crystallographic data for the structure in this Letter have been deposited with the Cambridge Crystallographic Data Centre as Supplementary Publication Number CCDC 713316. Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK [fax: +44 1223 336033 or email: deposit@ccdc.cam.ac.uk]. Selected crystallographic data: empirical formula C₁₉H₂₇N₃O, crystal system, space group: monoclinic, P212121; important bond lengths: C16–C17 1.357(3), N1–C17 1.340(3), N3–C16 1.355(3), N2–N3 1.324(2), N2–N1 1.361(2).
12. *Selected data for 8*: mp 188 °C (from MeOH–H₂O); IR ν_{\max} 3459 and 3150 (NH); ^1H NMR (500 MHz, DMSO- d_6): δ 0.93 (s, 3H, H-18), 1.42 (H-7 α), 1.57 (H-11 β), 1.68 (H-8), 1.78 (H-12 α), 1.91 (H-7 β), 2.12 (H-14), 2.19 (H-12 β), 2.30 (H-9), 2.39 (H-11 α), 2.41 (H-15 β), 2.69 (dd, 1H, $J_{14,15\alpha} = 6.4$, $J_{15\alpha,15\beta} = 14.3$ Hz, H-15 α), 2.82 (m, 2H, H-6 α , H-6 β), 5.04 (s, 2H, PhCH₂O), 6.73 (d, 1H, $J_{2,4} = 2.5$ Hz, H-4), 6.76 (dd, 1H, $J_{2,4} = 2.5$, $J_{1,2} = 8.5$ Hz, H-2), 7.18 (d, 1H, $J_{1,2} = 8.5$ Hz, H-1), 7.32–7.43 (5H, Ph), 14.03 (br s NH); ^{13}C NMR (125 MHz, DMSO- d_6): δ 18.29 (C-18), 23.12 (C-15), 25.66 (C-11), 26.92 (C-7), 29.06 (C-6), 33.78 (C-12), 36.97 (C-8), 39.10 (C-13), 43.74 (C-9), 60.62 (C-14), 68.98 (OCH₂, benzyl), 112.30 (C-2), 114.59 (C-4), 125.94 (C-1), 127.50 (2 \times *m*-CH, Ph), 127.68 (*p*-CH, Ph), 128.39 (2 \times *o*-CH, Ph), 132.16 (C-10), 137.32 (C-5), 137.38 (qC-benzyl), 151.18 (C-16), 156.23 (C-3), 161.34 (C-17); HR MS: m/z 386.2219 ($\text{M}^+ + \text{H}$); calcd for C₂₅H₂₈N₃O: 386.2227.
13. *Selected data for 9*: mp 268 °C (from benzene–acetone); IR ν_{\max} 3230 (OH and NH); ^1H NMR (250 MHz, acetone- d_6): δ 1.01 (s, 3H, H-18), 6.56 (d, 1H, $J_{2,4} = 2.0$ Hz, H-4), 6.62 (dd, 1H, $J_{2,4} = 2.0$, $J_{1,2} = 8.4$ Hz, H-2), 7.12 (d, 1H, $J_{1,2} = 8.4$ Hz, H-1), 8.03 (s, 1H, OH), 13.29 (br s, 1H, NH); ^{13}C NMR (62.9 MHz, acetone- d_6): δ 18.71 (C-18), 24.18 (C-15), 26.93 (C-11), 28.33 (C-7), 30.15 (C-6), 35.00 (C-12), 38.54 (C-8), 40.52 (C-13), 45.29 (C-9), 62.08 (C-14), 113.69 (C-2), 116.03 (C-4), 126.84 (C-1), 131.76 (C-10), 138.28 (C-5), 152.74 (C-16), 156.11 (C-3), 162.94 (C-17). HR MS: m/z 296.1765 ($\text{M}^+ + \text{H}$); calcd for C₁₈H₂₂N₃O: 296.1757.
14. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, T. J.; Bokesch, H.; Kenney, S.; Boyd, R. M. *J. Natl. Cancer Inst.* **1990**, *82*, 1107–1112.